All Stories

  1. Effects of functionalized silver nanoparticles on aggregation of human blood platelets
  2. MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study
  3. Sepsis-associated thrombocytopenia
  4. Pharmacokinetics and bio-distribution of novel super paramagnetic iron oxide nanoparticles (SPIONs) in the anaesthetized pig
  5. Intestinal microbiota transplant – current state of knowledge
  6. The Nanopharmacology and Nanotoxicology of Nanomaterials: New Opportunities and Challenges
  7. Pharmacological characterization of nanoparticle-induced platelet microaggregation using quartz crystal microbalance with dissipation: comparison with light aggregometry
  8. CuO nanoparticles induce apoptosis by impairing the antioxidant defense and detoxification systems in the mouse hippocampal HT22 cell line: Protective effect of crocetin
  9. Biodistribution and pharmacokinetic studies of SPION using particle electron paramagnetic resonance, MRI and ICP-MS
  10. Nanodiagnostics, nanopharmacology and nanotoxicology of platelet–vessel wall interactions
  11. CdTe quantum dots induce activation of human platelets: implications for nanoparticle hemocompatibility
  12. Titanium dioxide nanoparticles enhance production of superoxide anion and alter the antioxidant system in human osteoblast cells
  13. Blood biocompatibility of surface-bound multi-walled carbon nanotubes
  14. Magnetic Nanoparticles in Cancer Theranostics
  15. Pegylation Increases Platelet Biocompatibility of Gold Nanoparticles
  16. Pharmacological and toxicological effects of co-exposure of human gingival fibroblasts to silver nanoparticles and sodium fluoride
  17. Nitric oxide-matrix metaloproteinase-9 interactions: Biological and pharmacological significance
  18. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells
  19. Platelets and photodynamic cancer therapy
  20. Nanoparticle Adhesion to the Cell Membrane and Its Effect on Nanoparticle Uptake Efficiency
  21. MMP inhibition by barbiturate homodimers
  22. Targeted Delivery of Transferrin-Conjugated Liposomes to an Orthotopic Model of Lung Cancer in Nude Rats
  23. Mechanisms of Toxicity of Amorphous Silica Nanoparticles on Human Lung Submucosal Cells in Vitro: Protective Effects of Fisetin
  24. Approaches to the safety assessment of engineered nanomaterials (ENM) in food
  25. Differential inhibition of tumour cell‐induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin
  26. Fisetin prevents fluoride- and dexamethasone-induced oxidative damage in osteoblast and hippocampal cells
  27. Design of Barbiturate–Nitrate Hybrids that Inhibit MMP-9 Activity and Secretion
  28. Amorphous silica nanoparticles aggregate human platelets: potential implications for vascular homeostasis
  29. The use of quartz crystal microbalance with dissipation (QCM-D) for studying nanoparticle-induced platelet aggregation
  30. Mechanisms of aggregation inhibition by aspirin and nitrate-aspirin prodrugs in human platelets
  31. N-Substituted homopiperazine barbiturates as gelatinase inhibitors
  34. Analysis of platelet function: role of microfluidics and nanodevices
  35. Isolation of Exosomes for Subsequent mRNA, MicroRNA, and Protein Profiling
  36. Isosorbide-Based Aspirin Prodrugs: Integration of Nitric Oxide Releasing Groups
  37. Platelet compatibility of PLGA, chitosan and PLGA–chitosan nanoparticles
  38. NANOINTERACT: A rational approach to the interaction between nanoscale materials and living matter?
  39. A differential release of matrix metalloproteinases 9 and 2 during coronary artery bypass grafting and off-pump coronary artery bypass surgery
  40. Characterisation of the R3/1 cell line as an alveolar epithelial cell model for drug disposition studies
  41. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK
  42. Role of metalloproteinases in platelet function
  43. Nanoparticles: pharmacological and toxicological significance
  44. Selectins – potential pharmacological targets?
  45. Increased Alveolar and Plasma Gelatinases Activity during Postpump Syndrome: Inhibition by Inhaled Nitric Oxide
  46. Platelet Dysfunction in Asphyxiated Newborn Piglets Resuscitated with 21% and 100% Oxygen
  47. Alteration of Decreased Plasma NO Metabolites and Platelet NO Synthase Activity by Paroxetine in Depressed Patients
  48. Nanoparticle‐induced platelet aggregation and vascular thrombosis
  49. Combined administration of nitric oxide gas and iloprost during cardiopulmonary bypass reduces platelet dysfunction: A pilot clinical study
  50. Platelet–leukocyte aggregation induced by PAR agonists: regulation by nitric oxide and matrix metalloproteinases
  51. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation
  52. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder
  53. Membrane type‐1 matrix metalloproteinase stimulates tumour cell‐induced platelet aggregation: role of receptor glycoproteins
  54. Release of matrix metalloproteinase-9 during balloon angioplasty in patients with stable angina.
  55. Increased matrix metalloproteinase activity after canine cardiopulmonary bypass is suppressed by a nitric oxide scavenger
  56. Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study
  57. Identification, regulation and role of tissue inhibitor of metalloproteinases‐4 (TIMP‐4) in human platelets
  58. Mechanisms of action of proteinase‐activated receptor agonists on human platelets
  59. Role of von Willebrand factor in tumour cell‐induced platelet aggregation: differential regulation by NO and prostacyclin
  60. Pharmacological characteristics of solid‐phase von Willebrand factor in human platelets
  61. Cardiac surgery increases the activity of matrix metalloproteinases and nitric oxide synthase in human hearts
  62. Effects of LY117018 and the Estrogen Analogue, 17α-Ethinylestradiol, on Vascular Reactivity, Platelet Aggregation, and Lipid Metabolism in the Insulin-Resistant JCR:LA-cp Male Rat: Role of Nitric Oxide
  63. The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates
  64. Inhmition of matrix metalloproteinases(MMPs)prevents tissue injury and fibrotic complications in two rat models of inflammatory bowel disease
  65. Nitric Oxide and Platelet Function
  66. Regulation of Platelet Function
  67. The role of nitric oxide in the regulation of ion channels in airway epithelium: Implications for diseases of the lung
  68. Increased nitric oxide synthase activity after canine cardiopulmonary bypass is suppressed by S-nitrosoglutathione
  69. Differential Inhibition of Platelet Aggregation by Indomethacin and Inhaled Nitric Oxide in Critically Ill Infants
  70. NO effect on hemostasis
  71. Nitric Oxide-Mediated Regulation of Platelet Function
  72. The role of nitric oxide and metalloproteinases in the pathogenesis of hyperoxia‐induced lung injury in newborn rats
  73. Inhibition of nitric oxide generation unmasks vascular dysfunction in insulin‐resistant, obese JCR:LA‐cp rats
  74. Inhaled nitric oxide and inhibition of platelet aggregation in critically ill neonates
  75. Nitric oxide: Implications for placental biology
  76. Vascular wall reactivity in conductance and resistance arteries: differential effects of insulin resistance
  77. Vascular wall reactivity in conductance and resistance arteries: differential effects of insulin resistance
  78. Nitric oxide and platelet function: Implications for neonatology
  79. Release of gelatinase A during platelet activation mediates aggregation
  80. Regulation of Platelet Function by Nitric Oxide
  81. Nitric oxide: Implications for placental biology
  82. [9] Nitric oxide in platelets
  83. Nitric oxide— biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis
  84. The formation of nitric oxide donors from peroxynitrite
  85. Biological Significance of Nitric Oxide
  86. Nitric Oxide: Biological Mediator, Modulator and Effector
  87. Nitric oxide donors inhibit platelet spreading on surfaces coated with fibrinogen but not with fibronectin
  88. Nitric oxide in the clinical arena
  89. Porcine ventricular endocardial cells in culture express the inducible form of nitric oxide synthase
  90. The Biological and Pharmacological Role of Nitric Oxide in Platelet Function
  91. S‐nitroso‐glutathione inhibits platelet activation in vitro and in vivo
  92. Modulation of platelet aggregation by an l-arginine-nitric oxide pathway
  93. Endothelium-derived relaxing factor
  94. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium
  95. Inhibition of human platelet aggregation by vitamin K
  96. Prostacyclin prolongs viability of washed human platelets
  97. Conversion of exogenous arachidonic acid to prostaglandins in the pulmonary circulation in vivo A human and animal study
  98. Angiotensin-induced release of prostacyclin (PGI2) into circulation of anaesthetized cats
  99. Nitric Oxide, Platelet Function, Myocardial Infarction and Reperfusion Therapies
  100. The Nitric Oxide-Endothelin-1 Connection